Indole

Indole

SCHEMBL2347749

CCC(=O)C(=O)O.c1ccc2[nH]ccc2c1

nearest known ligand 0.57

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.57
CA1 P00915 1/20 0.57
CA2 P00918 1/20 0.57
ITGB2 P05107 1/20 0.57
ICAM1 P05362 1/20 0.57
ITGAL P20701 1/20 0.57
CA4 P22748 1/20 0.57
CA6 P23280 1/20 0.57
AHR P35869 1/20 0.57
ADK P55263 1/20 0.57
CTNNB1 P35222 2/20 0.44
WNT3A P56704 2/20 0.44
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
HPGD P15428 2/20 0.41
ENPP2 Q13822 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ESR1 P03372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indole SCHEMBL1614937 0.88 TRPA1 (0.63) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL28129119 0.88 TRPA1 (0.63) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL31188952 0.88 TRPA1 (0.63) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL28113892 0.85 TRPA1 (0.59) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL28833831 0.84 TRPA1 (0.63) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL2704553 0.84 TRPA1 (0.74) TRPA1CA1CA2ITGB2ICAM1
Oxaloacetate SCHEMBL10680938 0.83 TRPA1 (0.57) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL1714302 0.83 TRPA1 (0.61) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL31119874 0.82 TRPA1 (0.65) TRPA1CA1CA2ITGB2ICAM1
Indole SCHEMBL560095 0.82 TRPA1 (0.65) TRPA1CA1CA2ITGB2ICAM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819697-B1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS UNIV MAINZ JOHANNES GUTENBERG (DE) 2012-08-01 EP disclosed
US-8008320-B2 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors Johannes Gutenberg-Universitatis (DE) 2011-08-30 US disclosed
US-20090306124-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS JOHANNES GUTENBERG-UNIVERSITAT MAINZ (DE) 2009-12-10 US disclosed
EP-1819697-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS Johannes Gutenberg-Universität Mainz (DE) 2007-08-22 EP disclosed
WO-2006061212-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS Johannes Gutenberg-Universität Mainz (DE) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306124-A1 3-(INDOLYL)-4-ARYLMALEIMIDE DERIVATIVES AND THEIR USE AS ANGIOGENESIS INHIBITORS FLT4, KDR, FLT1 TRPA1 3667/4885CA1 1501/4885CA2 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.